For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years ...

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

In this retrospective cohort study, tirzepatide dispensations were found to have increased significantly following approval ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

The annual meeting of the American College of Physicians (Internal Medicine Meeting) was held from April 3 to 5 in New Orleans and was attended by internal medicine physicians, adult medicine ...

Physicians are turning to other options, including older, cheaper medications, as compounding GLP-1s comes to an end.

New research to be presented at the European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that around ...

You may know about tirzepatide, also known as Mounjaro or Zepbound, due to its popularity for those looking to lose weight or treat diabetes. Now, researchers have gotten it approved to treat sleep ...

A new study reveals that taking tirzepatide once a week can lead to significant and long-lasting weight loss for up to three ...

To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

The study finds better A1c lowering and weight reduction, but an expert clinician says practical issues may pose barriers.